AMRI   4Q Revenues: $67.1 million (flat) 4Q Earnings: $4.5 million (+137%) FY Revenues: $246.6 million (+9%) FY Earnings: $12.7 million (loss of $3.8 million FY12) Comments: Contract revenue for the quarter was a record $59.7 million, up 1%. Royalty revenue in the quarter was $7.4 million, down 9%, and includes royalties from the Allegra products as well as $2.3 million from sales of certain amphetamine salts sold by Actavis. Contract revenue for the year was a record $210.0 million, up 11%,...